Blis will research and develop probiotics - naturally occurring bacteria with "built-in" defences against disease-causing bacteria - to protect against upper respiratory tract infections common in infants.
Under the agreement, Nestle will finance research to develop probiotics suitable to use in infant formula up to the clinical trial phase. Nestle will take responsibility for clinical studies.